Daiwa: Raises JD Health's target price to HK$68.8, maintains "in line with market" rating.

Morgan Stanley released a research report stating that it has raised the target price of JD Health from HK$60 to HK$68.8, using discounted cash flow valuation, and maintained a "market perform" rating. The report stated that, considering JD Health's third quarter performance, the company is benefiting from the growth in direct sales and service revenue, with total revenue forecasts for 2025 to 2027 being raised by 1.4%. Additionally, as the scale of drug sales expands and advertising revenue increases, the company's gross margin shows an upward trend. The company has raised its earnings forecasts by 9%, 13%, and 13% respectively for the period.